For research use only. Not for therapeutic Use.
UNBS5162 (Cat.No:I005666) is a novel naphthalimide that decreases CXCL chemokine expression in experimental prostate cancers; the mean antiproliferative activity IC50 value is 17.9 uM for 9 cancer cell lines; hydrolysis product of UNBS3157.
| Catalog Number | I005666 |
| CAS Number | 956590-23-1 |
| Synonyms | UNBS-5162 |
| Molecular Formula | C17H18N4O3 |
| Purity | ≥95% |
| Target | Immunology/Inflammation |
| Solubility | DMSO: ≤ 21.5 mg/mL |
| Storage | Store at -20°C |
| IC50 | 4.7-46.5 uMcancer cell line) |
| IUPAC Name | [2-[2-(dimethylamino)ethyl]-1,3-dioxobenzo[de]isoquinolin-5-yl]urea |
| InChI | InChI=1S/C17H18N4O3/c1-20(2)6-7-21-15(22)12-5-3-4-10-8-11(19-17(18)24)9-13(14(10)12)16(21)23/h3-5,8-9H,6-7H2,1-2H3,(H3,18,19,24) |
| InChIKey | WCKZRLOUKYFJDY-UHFFFAOYSA-N |
| SMILES | CN(C)CCN1C(=O)C2=CC=CC3=CC(=CC(=C32)C1=O)NC(=O)N |
| Reference | </br>1:Phase I trial of UNBS5162, a novel naphthalimide in patients with advanced solid tumors or lymphoma. Mahadevan D, Northfelt DW, Chalasani P, Rensvold D, Kurtin S, Von Hoff DD, Borad MJ, Tibes R.Int J Clin Oncol. 2013 Oct;18(5):934-41. doi: 10.1007/s10147-012-0475-8. Epub 2012 Oct 11. PMID: 23053399 </br>2:UNBS5162, a novel naphthalimide that decreases CXCL chemokine expression in experimental prostate cancers. Mijatovic T, Mahieu T, Bruyère C, De Nève N, Dewelle J, Simon G, Dehoux MJ, van der Aar E, Haibe-Kains B, Bontempi G, Decaestecker C, Van Quaquebeke E, Darro F, Kiss R.Neoplasia. 2008 Jun;10(6):573-86. PMID: 18516294 Free PMC Article |
